DiaSorin stock gains 3.59 percent above its prior close

Published on 10/06/2026 at 14:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

DiaSorin stock trades at EUR 78.83 on October 6, 2026 versus EUR 76.10. H1 2026 revenue was EUR 602 million, flat at constant rates.

Techniker im Reinraum bedienen automatisierte Diagnostikgeräte in modernem Biotech-Labor — Modernes Diagnostiklabor von DiaSorin S.p.A., ISIN IT0003497168, zeigt präzise Biotech-Produktion und klinische Fertigung, Illustration mit AI erstellt.

DiaSorin stock gained 3.59 percent to EUR 78.83 at Lang & Schwarz on October 6, 2026 at 2:00 p.m. CEST, versus the prior close of EUR 76.10. The move comes against a mixed first-half operating picture, with revenue stable at constant exchange rates but profitability lower.

First-half revenue stays flat

In its Q2 2026 earnings call transcript, Yahoo Finance reported that DiaSorin generated EUR 602 million of revenue in the first half of 2026, flat at constant exchange rates compared with the first half of 2025. At current exchange rates, revenue declined 3 percent because of a EUR 20 million foreign-exchange headwind.

The quarterly trend improved in the second quarter of 2026. Revenue grew 4 percent at constant exchange rates and 3 percent at current exchange rates, while the adjusted EBITDA margin reached 33 percent in the quarter, up from 31 percent in the first quarter.

Guidance meets a weaker profit base

Adjusted EBIT totaled EUR 149 million in the first half of 2026, down 10 percent at constant exchange rates and 12 percent at current exchange rates, according to Yahoo Finance. EBITDA was EUR 194 million, down 7 percent at constant exchange rates, while the EBITDA margin was 32 percent.

Management confirmed full-year 2026 guidance for revenue growth of 5 percent to 6 percent and an adjusted EBITDA margin of 32 percent to 33 percent. The key tension is clear: second-quarter growth improved, but China, foreign exchange and investment for the LIAISON NES launch continue to weigh on the year-to-date earnings base.

Analyst target remains below price

Markets Insider reported on September 11, 2026 that Morgan Stanley raised its DiaSorin price target to EUR 71 from EUR 65 while retaining an Equal Weight rating. That target remains below the EUR 78.83 Lang & Schwarz price, making the stock reaction stronger than the latest published target revision.

Stock trades near its yearly high

The Lang & Schwarz price of EUR 78.83 on October 6, 2026 sits within the EUR 52.34 to EUR 80.38 52-week range. The quote is EUR 1.55 below the 52-week high, while the market capitalization was EUR 3.9 billion on the same date.

DiaSorin is listed as DIA on Borsa Italiana under ISIN IT0003492391, according to Borsa Italiana. The company develops, manufactures and markets in vitro diagnostic reagents, leaving investors to weigh improving quarterly growth against lower first-half profitability.

EUR 78.83 quote sets the frame

DiaSorin was trading at EUR 78.83 at Lang & Schwarz on October 6, 2026 at 2:00 p.m. CEST, up 3.59 percent versus the EUR 76.10 prior close dated October 5, 2026. The further course of trading is shown by the continuously updated real-time quote of DiaSorin stock.